150 related articles for article (PubMed ID: 37775668)
1. Cancer Cell Silicification and Surface Functionalization to Create Microbial Mimetic Cancer Vaccines.
Medina L; Kaehr B; Serda RE
Methods Mol Biol; 2024; 2720():209-219. PubMed ID: 37775668
[TBL] [Abstract][Full Text] [Related]
2. Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns.
Guo J; De May H; Franco S; Noureddine A; Tang L; Brinker CJ; Kusewitt DF; Adams SF; Serda RE
Nat Biomed Eng; 2022 Jan; 6(1):19-31. PubMed ID: 34725505
[TBL] [Abstract][Full Text] [Related]
3. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.
Belnoue E; Mayol JF; Carboni S; Di Berardino Besson W; Dupuychaffray E; Nelde A; Stevanovic S; Santiago-Raber ML; Walker PR; Derouazi M
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013258
[TBL] [Abstract][Full Text] [Related]
4. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
5. Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams SF; Grimm AJ; Chiang CL; Mookerjee A; Flies D; Jean S; McCann GA; Michaux J; Pak H; Huber F; Neal C; Dangaj D; Bassani-Sternberg M; Rusakiewicz S; Facciabene A; Coukos G; Gimotty PA; Kandalaft LE
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817208
[TBL] [Abstract][Full Text] [Related]
6. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
[TBL] [Abstract][Full Text] [Related]
7. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
8. Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine.
Barrio-Calvo M; Kofoed SV; Holste SC; Sørensen AB; Viborg N; Kringelum JV; Kleine-Kohlbrecher D; Steenmans CS; Thygesen CB; Rønø B; Friis S
Front Immunol; 2023; 14():1234912. PubMed ID: 37720215
[TBL] [Abstract][Full Text] [Related]
9. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
10. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
Front Immunol; 2018; 9():776. PubMed ID: 29867922
[TBL] [Abstract][Full Text] [Related]
11. Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines.
Aguilar-Gurrieri C; Barajas A; Rovirosa C; Ortiz R; Urrea V; de la Iglesia N; Clotet B; Blanco J; Carrillo J
Cancer Immunol Immunother; 2023 Jul; 72(7):2113-2125. PubMed ID: 36820900
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
14. Activated B lymphocytes and tumor cell lysate as an effective cellular cancer vaccine.
Oxley KL; Hanson BM; Zani AN; Bishop GA
Cancer Immunol Immunother; 2021 Nov; 70(11):3093-3103. PubMed ID: 33765210
[TBL] [Abstract][Full Text] [Related]
15. One-step artificial antigen presenting cell-based vaccines induce potent effector CD8 T cell responses.
Su Q; Igyártó BZ
Sci Rep; 2019 Dec; 9(1):18949. PubMed ID: 31831802
[TBL] [Abstract][Full Text] [Related]
16. Cognate MHC-TCR interaction leads to apoptosis of antigen-presenting cells.
Setterblad N; Blancheteau V; Delaguillaumie A; Michel F; Bécart S; Lombardi G; Acuto O; Charron D; Mooney N
J Leukoc Biol; 2004 Jun; 75(6):1036-44. PubMed ID: 14982950
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Particles for Cancer Vaccines: Connecting the Inherent Supply Chain.
Xia Y; Song T; Hu Y; Ma G
Acc Chem Res; 2020 Oct; 53(10):2068-2080. PubMed ID: 32945648
[TBL] [Abstract][Full Text] [Related]
18. Cell-based vaccines for the stimulation of immunity to metastatic cancers.
Ostrand-Rosenberg S; Pulaski BA; Clements VK; Qi L; Pipeling MR; Hanyok LA
Immunol Rev; 1999 Aug; 170():101-14. PubMed ID: 10566145
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
20. Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.
Chiozzini C; Olivetta E; Sanchez M; Arenaccio C; Ferrantelli F; Leone P; Federico M
J Mol Med (Berl); 2019 Aug; 97(8):1139-1153. PubMed ID: 31161312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
